UNSPSC 51263154: Bucindolol hydrochloride

This classification denotes a beta-adrenergic blocking agent with the molecular formula C22H25N3O2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier SH683G4QII, chemically known as 2-(2-hydroxy-3-((2-(3-indolyl)-1,1-dimethylethyl)amino)propoxy)benzonitrile hydrochloride but more generally known as bucindolol hydrochloride, which bears US NIH Compound Identifier 51044. European Medicines Agency schedules Bucindolol hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00886MIG.

Most nations, for tariff and trade purposes, schedule bucindolol hydrochloride under HS 29339990 and SITC 51577. As of Q4 2014, BUCINDOLOL HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: CC(C)(CC1C[NH]C2C1CCCC2)NCC(COC3CCCCC3C#N)O.CL.

UNSPSC 51263154 Bucindolol hydrochloride is a Commodity code for pharmaceutical products, but the most recent state and local procurement activity tagged under this code shows no purchases of bucindolol itself. Instead, Seminole County, Florida posted an IFB in June 2026 for Naloxone and Safe Drug Deactivation Systems—products unrelated to the code's nominal scope. The mismatch suggests either a tagging error in the county's procurement system or that the code is being used as a catchall for pharmaceutical-adjacent health and safety supplies. State and local governments procuring under this code appear to include county health departments and community health authorities focused on emergency response and substance-abuse intervention, though the recent-opportunities block provides insufficient data to characterize the issuing-body mix broadly or identify repeat buyers.

The sole recent opportunity with decision-relevant detail is Seminole County's IFB 60459723LAS, posted June 30, 2026, with a response deadline of July 26, 2023, for 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida. The contract carries a two-year initial term with a one-year renewal option, fixed-fee pricing, full shipping and delivery responsibility on the vendor, E-Verify compliance, and potential FEMA funding with associated federal compliance obligations. Geographic activity is limited to Florida in the recent-opportunities block; no other states appear. The code shows sparse recent activity overall, and the single posted opportunity diverges significantly from the pharmaceutical product the code nominally describes, limiting reliable market characterization at this time.